




GHIT Fund 2.0 Strategic Plan


FY2018–FY2022

HOW WE WORK




Innovative Financing for Global Health R&D

GHIT Fund (GHIT) is a global health R&D fund, which invests in non-profit product development for HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases. GHIT's funding partners, including the Government of Japan, Bill & Melinda Gates Foundation, the Wellcome Trust, and global life sciences companies, have committed over USD 200M for GHIT 2.0 (FY2018 - 2022).




Global Open Innovation

GHIT catalyzes open innovation between Japanese and non-Japanese entities across the globe to accelerate product development for patients who suffer from neglected diseases. GHIT invests in innovative product development by integrating Japan's science and pharmaceutical technologies and capabilities with global networks and resources.



Rigorous Portfolio Management

GHIT monitors and evaluates project progress biannually together with product development partners using gold standard industry metrics. We promptly retire research that does not bear fruit. This approach enables efficient use of our limited resources and helps us realize tangible impact more quickly.



Access & Delivery Strategy Appraisal

GHIT provides strategic guidance to product development partners on their access and delivery strategies for late-stage candidates, in collaboration with domestic and international partners. Key issues considered include demand forecast; regulatory strategy; financing strategy; manufacturing, procurement, and supply chain; and policy and advocacy.



GHIT 1.0: Tangible Results

As of March, 2018

FY2013–FY2017



R&D: Investments in Product Development



Excellence through Good Governance

Japan's first international Public Interest Incorporated Association

Certified in June, 2014 as Japan's first internationally governed and managed public interest incorporation

Managed conflicts of interest through good governance

Established transparent, independent governance model that features a robust firewall between funders and institutional investment and organizational decision-making; additionally, all industry partners are precluded from any investment decision making and all institutional operations

Investment, not philanthropy

Introduced rigorous investment management system to track and evaluate progress, end unsuccessful projects early, and accelerate innovations



Financial Strategies

Expanded funding partners and increased funding capacity

Launched in 2013 as a USD 100 million fund with 10 partners; today in 2017, as a result of new and renewed commitments, funding exceeds USD 145 million, with 26 partners


Leveraged co-investment

Leveraged investment impact through co-investment from domestic and international entities

Replenished GHIT 2.0

Secured commitments of over USD 200 million for GHIT 2.0 replenishment

Total Investment	Total Invested Partnerships	Total Product Development Partners	GHIT 1.0 Committed Capital	GHIT Cumulative Committed Capital
USD 132 _M	74	103	USD 145 _M	USD 345 _M



Partnership for Delivery

Developed Access Policy

Developed GHIT Data Access Policy and Product Access Policy

Defined Target Product Profiles

Solicited proposals based on clearly defined target product profiles (TPPs) for low- and middle-income countries; TPPs align the unique needs of end-users with desired product attributes and performance criteria

Partnered with United Nations Development Programme (UNDP)

Worked closely with UNDP's Access & Delivery Partnership, which helps low- and middle-income countries address bottlenecks within their health systems so that GHIT-funded innovations can reach more people, faster

Developed Access & Delivery Strategy

Developed late-stage candidate access and delivery strategies framework for development partners, including such issues as demand forecast; regulatory strategy; financing strategy; manufacturing, procurement, and supply chain; and policy and advocacy; initiated its appraisals

Product development organizations partnering with Japan



GHIT 2.0: Strategic Plan



FY2018–FY2022

GHIT utilizes Japanese science and pharmaceutical capabilities to accelerate product development (i.e., drugs, vaccines, and diagnostics) for HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases



R&D: Investments in Product Development


Further leverage innovations from Japanese biopharma and academia



Excellence through Good Governance

Ensure and further enhance corporate governance and institutional development

- Two successful audits by the Cabinet Office of Japan (conducted every three years)
- Five successful financial audits by an external and independent auditor
- Five successful internal audits by the GHIT management team (results reported to Chief Executive Officer & Board of Directors)
- Biennial review and sign-off by Board of Directors of updated GHIT policies including Governance Manual




Financial Strategies

Maximize efficiencies in fund management and co-funding strategies

- Maintain overhead cost (at or below 5%)
Maintain uniquely low overhead cost in order to maximize investments in R&D
- Increase leveraging factor (to 2.0)
$$\text{Leveraging factor} = (\text{GHIT's investment} + \text{co-investment by other organizations}) / (\text{GHIT's investment}) = 1.5 \text{ as of December, 2017}$$

Develop and execute a replenishment plan for GHIT 3.0

- Successfully replenish GHIT 3.0 (FY2023 - FY2027)
Ensure sustainable operations of GHIT and continued acceleration of product development



Design of clinical trials (e.g., PhIa/b, PhIIa/b) and point of testing for proof of concept depends on regulatory science; depiction above is only representative.

Refine strategies to maximize global health R&D excellence and outcomes

- Six preclinical investments and four clinical investments reviewed for effectiveness in the field
- Annual portfolio review approved by the Portfolio and Launch Strategy Committee (PLSC), a standing committee of the GHIT Board of Directors



Partnership for Delivery

Strengthen capacity to appraise access and delivery strategies for late-stage candidates

- 10 access and delivery strategies for late-stage investments reviewed by PLSC, and reported to the Board of Directors

Leverage UNDP and other global network partners for product delivery preparedness

- Six access and delivery strategies shared and discussed with UNDP and other global partners
- Six meetings convened between development partners and relevant global partners for each of the access and delivery strategies aforementioned with the goal of in-country access and delivery support
- Present GHIT's access and delivery strategies at more than 20 conferences or events

Partners & Sponsors

Full Partners



Associate Partners



Affiliate Partners



Sponsors



GHIT Fund

Global Health Innovative Technology Fund

Ark Hills Sengokuyama Mori Tower 25F,
1-9-10 Roppongi, Minato-ku,
Tokyo 106-0032 Japan
TEL: +81-36441-2032 FAX: +81-36441-2031
www.ghitfund.org

ver1.2 2018.3.31

GHIT invests using Japanese yen. US dollar amounts represent conversions from Japanese yen, solely for the reader's convenience, at JPY 100 = USD 1.

